SCREENING
To help detect colorectal cancer early, when treatment is most effective, we developed Shield™, our FDA-approved blood-based screening test for adults 45 and older at average risk for colorectal cancer.
Learn More
Our Approach
We’re dedicated to the belief that precision oncology has the extraordinary power to improve patient outcomes.
Supporting Patients
at Every Stage of Cancer
Since 2012, we’ve reimagined how cancer is found, treated, and monitored using simple blood tests that give patients and doctors critical insights at every step. Today, we continue to lead with innovation—advancing care with blood and tissue tests, real-world data, and AI-powered insights that are improving outcomes for patients worldwide.
Advancing Cancer Care Through Insight & Innovation
Unlocking Insights to help find, treat, and monitor cancer.
-
-
TREATMENT SELECTION
Guardant360® Liquid is a blood-based test that analyzes tumor DNA circulating in the blood to help doctors identify targeted therapies for patients with advanced solid cancers. As an alternative to tissue biopsies, it provides comprehensive genomic profiling to guide personalized treatment across a wide range of cancers.
Learn More -
TREATMENT SELECTION
Guardant360® Tissue provides deeper insights into a tumor’s biology through comprehensive analysis of genomics, transcriptomics, & epigenomics. These insights can inform the use of therapies and enables more detailed tumor classification, supporting new precision oncology research and clinical applications.
Learn More -
MRD + MONITORING
Guardant Reveal® is a tissue-free liquid biopsy test that detects minimal residual disease—cancer remaining after treatment—and monitors for recurrence in early-stage colorectal, breast, and lung cancers. It also tracks treatment response in patients with late-stage solid tumors, helping doctors guide treatment decisions.
Learn More -
POWERING CLINICAL DECISIONS
InfinityAI is our purpose-built artificial intelligence and machine learning technology that transforms Guardant Health’s rich multiomic datasets with clinical data into real-world evidence and actionable insights.
Learn More
Conquering Cancer With Data
Learn how blood, and the insights it holds, has the power to transform cancer care across the continuum.
PUTTING PATIENTS FIRST
Expanding Access for All
Cancer touches everyone, but not everyone has equal access to the latest advances in care. We partner with doctors, researchers, policymakers, and patient advocates to expand access to screening and clinical trials—especially in underserved populations. And with broad coverage from Medicare and private insurers, representing over 300 million lives, we continue to advocate so every patient who needs our tests can benefit from them.
300M+
LIVES COVERED
